Study Shows Only 40 Percent of Patients with Metastatic Colon Cancer Receive Guideline-Recommended Biomarker Testing

NEXT STORY
Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta® and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma
PREV STORY
APHINITY six-year results strengthen evidence of clinical benefit with Roche’s Perjeta-based regimen
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Clearside Biomedical Announces Second Quarter 2019 Financial Results and Provides Corporate Update

author_avatar
NASDAQ Market News

Revive Therapeutics Announces Submission of Investigational New Drug Application (IND) with U.S. FDA for Phase 3 Confirmatory Study for Bucillamine in COVID-19

author_avatar
NASDAQ Market News

Antiseptics, Disinfectants Global Market to Achieve Steady Growth

WELLESLEY, Mass., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Increasing awareness about the importance of ...

author_avatar
NASDAQ Market News